A recent study by Pillinger et al. demonstrated that BTK was activated in the downstream of the FLT3-ITD in AML and that ibrutinib induced survival and proliferation pathways including AKT, STAT5 and MAPK via targeting FLT3-ITD [25]. This evidence concerns the gene FLT3 and acute myeloid leukemia.